Efficacy and Safety Study of AI201901 in Allergic Rhinitis Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

210

Participants

Timeline

Start Date

April 20, 2021

Primary Completion Date

March 3, 2023

Study Completion Date

May 2, 2023

Conditions
Allergic Rhinitis Due to Allergens
Interventions
DRUG

AI201901

Twice daily inhaled AI201901 for 4 weeks

DRUG

Azelastine Hydrochloride

Twice daily inhaled Azelastine Hydrochloride for 4 weeks

Trial Locations (1)

Unknown

Dokuz Eylul University, Izmir

All Listed Sponsors
collaborator

Istanbul Umraniye Training and Research Hospital

UNKNOWN

collaborator

Diskapi Yildirim Beyazit Education and Research Hospital

OTHER_GOV

collaborator

Antalya Training and Research Hospital

OTHER_GOV

collaborator

Dokuz Eylul University

OTHER

collaborator

Ankara City Hospital Bilkent

OTHER

collaborator

Kahramanmaras Sutcu Imam University

OTHER

collaborator

Uludag University

OTHER

collaborator

Karadeniz Technical University

OTHER

collaborator

Kartal Dr. Lütfi Kirdar City Hospital

UNKNOWN

lead

Abdi Ibrahim Ilac San. ve Tic A.S.

INDUSTRY